These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial. Waddington-Cruz M; Ackermann EJ; Polydefkis M; Heitner SB; Dyck PJ; Barroso FA; Wang AK; Berk JL; Dyck PJB; Monia BP; Hughes SG; Tai L; Jesse Kwoh T; Jung SW; Coelho T; Benson MD; Gertz MA Amyloid; 2018 Sep; 25(3):180-188. PubMed ID: 30169969 [TBL] [Abstract][Full Text] [Related]
48. Unexplained cardiac failure leading to the identification of a Belgian family affected by hereditary amyloidosis. De Pasqual A; Biessaux Y; Blettard N; Crémers S; Caers J Acta Clin Belg; 2013; 68(4):303-5. PubMed ID: 24455802 [TBL] [Abstract][Full Text] [Related]
49. Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation. Matsushima M; Yabe I; Tsuda M; Sakakibara M; Shimamura T; Sasaki H Intern Med; 2017 Dec; 56(23):3231-3235. PubMed ID: 28943540 [TBL] [Abstract][Full Text] [Related]
50. Progressive Multiple Mononeuropathy in a Patient With Familial Transthyretin Amyloidosis After Liver Transplantation. Seibert K; Wlodarski R; Sarswat N; Appelbaum D; Issa NP; Soliven B; Rezania K J Clin Neuromuscul Dis; 2022 Mar; 23(3):143-147. PubMed ID: 35188911 [TBL] [Abstract][Full Text] [Related]
51. Wild-Type Transthyretin Cardiac Amyloidosis Is Associated with Increased Antecedent Physical Activity. Lee YZJ; Fajardo J; Brown E; D'Adamo CR; Judge DP J Cardiovasc Transl Res; 2022 Aug; 15(4):689-691. PubMed ID: 35083733 [No Abstract] [Full Text] [Related]
52. Clinical manifestations in hereditary amyloidosis with the variant Glu54Gln transthyretin. Jercan A; Badelita S; Draghici M; Stoica E; Iacob S; Coriu D Amyloid; 2019; 26(sup1):31-32. PubMed ID: 31343281 [No Abstract] [Full Text] [Related]
53. [Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment]. Longhi S; Gagliardi C; Milandri A; Manuzzi L; Rapezzi C G Ital Cardiol (Rome); 2014 May; 15(5):293-300. PubMed ID: 25002169 [TBL] [Abstract][Full Text] [Related]
54. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan. Ueda M; Yamashita T; Misumi Y; Masuda T; Ando Y Amyloid; 2018 Sep; 25(3):143-147. PubMed ID: 30486687 [TBL] [Abstract][Full Text] [Related]
55. Systemic angiopathy and axonopathy in hereditary transthyretin amyloidosis with Ala97Gly (p. Ala117Gly) mutation: a post-mortem analysis. Koike H; Yasuda T; Nishi R; Ikeda S; Kawagashira Y; Iijima M; Sobue G; Katsuno M Amyloid; 2018 Jun; 25(2):141-142. PubMed ID: 29855203 [No Abstract] [Full Text] [Related]
56. Treatment of transthyretin cardiomyopathy with a TTR-specific antisense oligonucleotide (IONIS-TTR Benson MD; Ackermann EJ; Monia BP Amyloid; 2017 Mar; 24(sup1):134-135. PubMed ID: 28434337 [No Abstract] [Full Text] [Related]
57. First report of a rare mutation in a Polish patient with painful late-onset transthyretin amyloidosis. Hagenacker T; Brenck J; Kastrup O J Neurol Sci; 2014 Nov; 346(1-2):331-2. PubMed ID: 25130926 [No Abstract] [Full Text] [Related]
58. Cardiac Amyloidosis in a Child Presenting with Syncope: The First Reported Case and a Diagnostic Dilemma. Torpoco Rivera DM; Williams CT; Karpawich PP Pediatr Cardiol; 2022 Mar; 43(3):700-703. PubMed ID: 34783874 [TBL] [Abstract][Full Text] [Related]
59. Vitreal deposits in Val71Ala transthyretin amyloidosis. Suan D; Booth DR; Kennedy IH; Downie J; Earls P; Gottlieb D; Stewart GJ; Lin MW Intern Med J; 2012 Jan; 42(1):106-8. PubMed ID: 22276564 [No Abstract] [Full Text] [Related]
60. Rapidly Progressive Transthyretin-Mediated Amyloidosis in a Domino Liver Transplant Recipient of a Ser23Asn Donor. Dixit N; Castano A; Farr MJ; Traub R; Lentzsch S; Brown RS; Maurer MS; Brannagan TH J Clin Neuromuscul Dis; 2016 Mar; 17(3):142-5. PubMed ID: 26905915 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]